In this issue:
Ibrutinib for relapsed/refractory CLL
Real-world clinical experience of CLL registry
Real-world ibrutinib for relapsed/refractory CLL
Ibrutinib for relapsed CLL after allogeneic HSCT
Outcomes for chromosome abnormalities at CR in AML with abnormal karyotype at diagnosis
Sequential imatinib-based approach for Ph+ ALL
Switch to nilotinib vs. imatinib dose escalation in CML after suboptimal response
Cancer-related fatigue in HL
Anticoagulation for symptomatic calf DVT
Model for predicting post partum VTE risk
Please login below to download this issue (PDF)